Population pharmacokinetic/pharmacodynamic Modeling for Pegylated Recombinant Human Growth Hormone (

来源 :第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu | 被引量 : 0次 | 上传用户：lishashasky

【摘要】

：

【作者】

：

Xin Zheng Tao Liu Qian Zhao Pei Hu Ji Jiang

【机构】

：

Peking Union Medical College Hospital 41 Damucanghutong, Xicheng, Beijing, 100032, China

【出处】

：

第四届定量药理学与新药评价国际会议·2013(The 4th International Symposium in Qu

【发表日期】

：

2013年4期

下载到本地 , 更方便阅读

下载此文赞助VIP

声明 : 本文档内容版权归属内容提供方 , 如果您对本文有版权争议 , 可与客服联系进行内容授权或下架

论文部分内容阅读

Objective:CPRC-Y is a pegylatedrecombinant human growth hormone (rhGH) developed with the aim of reducing serum clearance and thereby prolonging the exposure leading to once-weekly sc administration.The purpose of this research was to construct appropriate models to characterize population pharmacokinetics (PK)for CPRC-Y and PK/pharmacodynamics(PD) for the efficacy biomarker Insulin-like Growth factor-1 (IGF-1).

其他文献

Pharmacokinetic-pharmacodynamic modeling of the anticancer effect of erlotinib in a human non-small

Aim:Erlotinib is used to treat non-small-cell lung cancer (NSCLC), which targets epidermal growth factor receptor (EGFR) tyrosine kinase.The aim of this study was to investigate the relationship betwe

会议

non-small-cell lung canceranticancer drugerlotinibepidermal growth factor rec

Preclinical Pharmacokinetic/Pharmacodynamic Models to Predict Schedule-Dependent Interaction Between

Purpose:To investigate the pharmacological effects of differenterlotinib (ER) and gemcitabine (GM) combination schedules byin vitro and in vivo experiments and PK/PD models in non-smallcell lung cance

会议

Pediatric physiologically based pharmacokinetic model and its applications in pediatric drug researc

Pediatric drug research is currently one of the new frontiers for clinical pharmacology.With the necessity of pediatric drug research and the special ethical considerations in pediatric clinical trial

会议

TOWARDS QUANTITATIVE PREDICTION OF IN VIVO BRAIN PENETRATION USING A PHYSIOLOGY BASED CNS DISPOSITIO

INTRODUCTION Drug discovery for central nervous system (CNS) disorders has been challenged with markedly high attrition rate.This has driven extensive preclinical and clinical CNS pharmacokinetic (PK)

会议

Apply established exposure-response model with different mechanism of actions to guide clinical tria

Background: Exposure-response model has been established in patients with psoriasis for Ustekinumab, a human immunoglobulin G1 kappa (IgG1k) monoclonal antibody that binds with high affinity to human

会议

Population pharmacokinetics of adefovir dipivoxil tablets in healthy Chinese volunteers

AIM: To develop a population pharmacokinetic model of adefovir dipivoxil in healthy volunteers and evaluate the effect of individual factors on the pharmacokinetics of adefovir dipivoxil.METHODS: Plas

会议

Population pharmacokinetics of mycophenolic acid and its main glucuronide metabolite: comparison bet

The objective of this study was to assess ethnic difference of mycophenolic acid (MPA) and 7-Omycophenolic acid glucuronide (MPAG) pharmacokinetics (PK) among Chinese and Caucasian healthy subjects by

会议

Assessing ethnic sensitivity by simulating pharmacokinetics in virtual Caucasian and Chinese populat

Background and Rationale: Physiologically-based pharmacokinetics (PBPK) modelling is a key component of model-based drug development and is increasingly embraced within the industry and regulatory aut

会议

Model-Based Drug Development for Oncology Protein Therapeutics

Biopharmaceutical industry has focused on cancer drug research and development in the past decades, however the success rate for oncology products is relatively low compared to other therapeutic areas

会议

Pharmacokinetic profile of ranibizumab is similar between Chinese and Caucasian patients with diabet

Purpose:Diabetic macular edema (DME) is a trequent manifestation of diabetic retinopathy which is the most common microvascular complications of diabetes mellitus, accounting for 13％ visual impairment

会议

Population pharmacokinetic/pharmacodynamic Modeling for Pegylated Recombinant Human Growth Hormone (

与本文相关的学术论文